Immune response to rb1-Regulated senescence limits radiation-Induced osteosarcoma formation

Journal of Clinical Investigation

Volumn 123, Issue 12, 2013, Pages 5351-5360

  Kansara, Maya ^a,b   Leong, Huei San ^a   Lin, Dan Mei ^a   Popkiss, Sophie ^a   Pang, Puiyi ^a   Garsed, Dale W ^a   Walkley, Carl R ^c   Cullinane, Carleen ^a,b   Ellul, Jason ^a   Haynes, Nicole M ^a   Hicks, Rod ^a,b   Kuijjer, Marieke L ^d   Cleton Jansen, Anne Marie ^d   Hinds, Philip W ^e   Smyth, Mark J ^a,b,f   Thomas, David M ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e TUFTS MEDICAL CENTER   (United States)

^f QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM 45; INTERLEUKIN 6; RETINOBLASTOMA 1 PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INFILTRATION; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOGENICITY; CELL INFILTRATION; CONTROLLED STUDY; GENE CASSETTE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; MOUSE; NATURAL KILLER T CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; RADIATION INDUCED NEOPLASM; RADIATION INDUCED OSTEOSARCOMA; RETINOBLASTOMA TUMOR SUPPRESSOR GENE; SENESCENCE; SENESCENCE ASSOCIATED SECRETORY PHENOTYPE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE;

ANIMALS; BONE NEOPLASMS; CALCIUM RADIOISOTOPES; CELL AGING; CYTOKINES; GENES, RETINOBLASTOMA; HUMANS; IMMUNOLOGIC SURVEILLANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, RADIATION-INDUCED; OSTEOBLASTS; OSTEOSARCOMA; PHENOTYPE; PROGNOSIS; RETINOBLASTOMA PROTEIN; RNA INTERFERENCE;

EID: 84890017939     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70559     Document Type: Article

References (64)

1. Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 2007;26(1):1-18
2. Toguchida J, et al. Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma. Nature. 1989;338(6211):156-158
3. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science. 1987; 235(4794):1394-1399
4. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer. 1995;75(8):2186-2195
5. Hansen MF, Cavenee WK. Retinoblastoma and osteosarcoma: the prototypic cancer family. Acta Paediatr Jpn. 1987;29(4):526-533
6. Eng C, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85(14):1121-1128
7. Huvos AG, Woodard HQ. Postradiation sarcomas of bone. Health Phys. 1988;55(4):631-636
8. Virtanen A, Pukkala E, Auvinen A. Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients. Int J Cancer. 2006;118(4):1017-1021
9. Hiebert SW, Chellappan SP, Horowitz JM, Nevins Jr. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev. 1992;6(2):177-185
10. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8(9):671-682
11. Alexander K, Hinds PW. Requirement for p27(KIP1) in retinoblastoma protein-mediated senescence. Mol Cell Biol. 2001;21(11):3616-3631
12. Thomas DM, et al. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell. 2001;8(2):303-316
13. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729-740
14. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88(5):593-602
15. Tiemann F, Hinds PW. Induction of DNA synthesis and apoptosis by regulated inactivation of a temperature- sensitive retinoblastoma protein. EMBO J. 1998; 17(4):1040-1052
16. Chow LM, et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 2011; 19(3):305-316
17. Coppe JP, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853-2868
18. Acosta JC, O'Loghlen A, Banito A, Raguz S, Gil J. Control of senescence by CXCR2 and its ligands. Cell Cycle. 2008;7(19):2956-2959
19. Kuilman T, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133(6):1019-1031
20. Markey MP, et al. Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function. Oncogene. 2007;26(43):6307-6318
21. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723
22. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465
23. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-1570
24. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature. 2012; 482(7385):405-409
25. Theoleyre S, et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer. 2005;5:123
26. Biller BJ, Guth A, Burton JH, Dow SW. Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J Vet Intern Med. 2010;24(5):1118-1123
27. Zhou Z, Lafleur EA, Koshkina NV, Worth LL, Lester MS, Kleinerman ES. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol Cancer Res. 2005;3(12):685-691
28. Schwinger W, et al. Feasibility of high-dose interleukin- 2 in heavily pretreated pediatric cancer patients. Ann Oncol. 2005;16(7):1199-1206
29. Strander H, et al. Adjuvant interferon treatment of human osteosarcoma. Recent Results Cancer Res. 1982; 80:103-107
30. Meyers PA, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol. 2008;26(4):633-638
31. Clarke AR. Murine models of neoplasia: functional analysis of the - suppressor genes Rb-1 and p53. Cancer Metastasis Rev. 1995;14(2):125-148
32. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature. 1992;359(6393):295-300.
33. Finkel MP, Jinkins P B, Biskis BO. Parameters of radiation dosage that influence production of osteogenic sarcomas in mice. Natl Cancer Inst Monogr. 1964;14:243-269
34. Walkley CR, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008; 22(12):1662-1676
35. Kopf M, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368(6469):339-342
36. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012; 8(9):1237-1247
37. Feyen JH, Elford P, Di Padova FE, Trechsel U. Interleukin-6 is produced by bone and modulated by parathyroid hormone. J Bone Miner Res. 1989; 4(4):633-638
38. Hong S, et al. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Immunol Rev. 1999;169:31-44
39. Mendiratta SK MW. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity. 1997;6(4):469-477
40. Cui J ST, Koseki H KM. Requirement for V a 14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278(5343):1623
41. Chan LL, Czerniak BA, Ginsberg LE. Radiationinduced osteosarcoma after bilateral childhood retinoblastoma. AJR Am J Roentgenol. 2000; 174(5):1288
42. Chauveinc L, et al. Osteosarcoma following retinoblastoma: age at onset and latency period. Ophthalmic Genet. 2001;22(2):77-88
43. Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 2010; 29(2):273-283
44. Muller K, Meineke V. Radiation-induced alterations in cytokine production by skin cells. Exp Hematol. 2007;35(4 suppl 1):96-104
45. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192(4):547-556
46. Givon T, Slavin S, Haran-Ghera N, Michalevicz R, Revel M. Antitumor effects of human recombinant interleukin-6 on acute myeloid leukemia in mice and in cell cultures. Blood. 1992;79(9):2392-2398
47. Revel M, et al. Interleukin-6: effects on tumor models in mice and on the cellular regulation of transcription factor IRF-1. Ann N Y Acad Sci. 1995; 762:342-355
48. Katz A, Sulman LM, Porgador A, Revel M, Feldman M, Eisenbach L. Abrogation of B16 melanoma metastasis by long term dose of interleukin-6 ther- apy. J Immunother Emphasis Tumor Immunol. 1993; 13(2):98-109
49. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2007;72(11):1605-1621
50. Dethlefsen C, Højfeldt G, Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 2013;138(3):657-664
51. Kang TW, et al. Senescence surveillance of premalignant hepatocytes limits liver cancer development. Nature. 2011;479(7374):547-551
52. di Carlo E, et al. Neutrophils in anti-cancer immunological strategies: old players in new games. J Hematother Stem Cell Res. 2001;10(6):739-748
53. Fielding CA, et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol. 2008;181(3):2189-2195
54. Metelitsa LS, et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med. 2004;199(9):1213-1221
55. Faunce DE, Sonoda K-H, Stein-Sreilein J. MIP- 2 recruits NKT cells to spleen during tolerance induction. J Immunol. 2001;166(1):313-321
56. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res. 2008;101:277-348
57. Swann JB, et al. Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood. 2009; 113(25):6382-6385
58. Asano T, McWatters A, An T, Matsushima K, Kleinerman ES. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin- 1 beta, tumor necrosis factor-alpha, interleukin- 6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther. 1994; 268(2):1032-1039
59. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol. 2003; 84(3):151-159
60. Cullinane C, et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res. 2005;65(21):9633-9636
61. Gronthos S, Zannettino ACW, Graves SE, Ohta S, Hay SJ. Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J Bone Miner Res. 1999;14(1):47-56
62. Morgan T, et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol. 2005;167(1):117-128
63. Kuijjer ML, et al. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer. 2012;51(7):696-706
64. Kansara M, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009;119(4):837-851